Alzheimer’s disease pipeline update – Lecanemab
September 27, 2022 - Biogen and Eisai announced positive topline results from the Phase 3 confirmatory Clarity AD trial of lecanemab, for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Top